Indigestion News and Research RSS Feed - Indigestion News and Research

Indigestion, known as ''upset stomach'' or ''dyspepsia'', meaning hard or difficult digestion, is a medical condition characterized by chronic or recurrent pain in the upper abdomen, upper abdominal fullness and feeling full earlier than expected when eating. It can be accompanied by bloating, belching, nausea, or heartburn.
FAST Upset Stomach offers one shot dose of Liquid Relief for people suffering from heartburn

FAST Upset Stomach offers one shot dose of Liquid Relief for people suffering from heartburn

First Aid Shot Therapy, makers of First Aid Shot Therapy Pain Relief, today announced the launch of its newest offering, First Aid Shot Therapy Upset Stomach. Upset Stomach is the second variant to be launched in the F.A.S.T. range of products and it is formulated to relive upset stomach symptoms. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
Cardiologist offers tips to keep heart healthy during holiday season

Cardiologist offers tips to keep heart healthy during holiday season

Physicians have long recognized a "holiday bump" in the number of heart attacks at this time of year. "It's small, but it's something that we notice," said Renato Santos, M.D., an interventional cardiologist at Wake Forest Baptist Medical Center. [More]
Health care practitioners should focus on getting calcium from diet, says researcher

Health care practitioners should focus on getting calcium from diet, says researcher

In recent years, studies have reported inconsistent findings regarding whether calcium supplements used to prevent fractures increase the risk of heart attack. [More]
FDA approves OTREXUP injection for adults with RA, children with active pJIA

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
Adempas drug gets FDA approval for treatment of pulmonary hypertension

Adempas drug gets FDA approval for treatment of pulmonary hypertension

The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs. [More]
Researchers identify potential drug target to recover from jet lag, disruptions in circadian system

Researchers identify potential drug target to recover from jet lag, disruptions in circadian system

University of Notre Dame researchers, as part of a collaborative effort, have identified a protein that potentially could be a target for drugs that would help people recover faster from jet lag and better adjust their circadian rhythms during rotational shift work. [More]
Experts share tips on preventing ovarian cancer

Experts share tips on preventing ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women. Approximately 22,000 women are diagnosed annually and 14,000 die from the disease. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention. [More]
Research suggests new models for study of Barrett's esophagus

Research suggests new models for study of Barrett's esophagus

Research focused on the regulation of the adult stem cells that line the gastrointestinal tract of Drosophila suggests new models for the study of Barrett's esophagus. [More]
Teva to present abstracts on AZILECT at MDS meeting

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society. [More]
Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Research presented at Digestive Disease Week explores new methods for managing digestive health through diet and lifestyle. [More]
Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva initiates enrollment in AZILECT Phase IV clinical study for PD-MCI

Teva Pharmaceutical Industries Ltd. announced today enrollment of the first patient in the MODERATO study - a Phase IV clinical study designed to evaluate the effect of AZILECT (rasagiline tablets) on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI). [More]
Viewpoints: Baker and Dingell urge efforts to cut gun deaths; Doctors as union workers

Viewpoints: Baker and Dingell urge efforts to cut gun deaths; Doctors as union workers

Gun violence now rivals traffic accidents as the leading cause of death by injury in the United States. Quite simply, gun violence threatens to overwhelm us. Americans are grappling for strategies to make sure that the horror that occurred in Newtown isn't repeated. [More]
Juxtapid receives FDA approval for treatment of rare cholesterol disorder

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments. [More]
Holiday stress and cold temperatures could lead to heart attacks if left unchecked

Holiday stress and cold temperatures could lead to heart attacks if left unchecked

Amid the frenzy of decorating, planning and shopping for the holidays, health may take a backseat. However, the stress brought on by these activities plus cold temperatures could lead to heart attacks or heart-related complications if left unchecked. [More]
Lone star tick causes alpha-gal meat sensitivity in regional population

Lone star tick causes alpha-gal meat sensitivity in regional population

Meat lovers living in the central and southern regions of the country might be opting for a vegetarian lifestyle if meat comes with an unwanted side of a life-threatening allergic reaction. According to a study presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), the lone star tick inhabiting these regions is the primary reason for what's known as a meat induced alpha-gal allergic reaction. [More]
Gentle chiropractic care improves child's overall health and well-being

Gentle chiropractic care improves child's overall health and well-being

Irritation to a young person's nervous system can begin in utero. The baby's position during delivery (natural or cesarean) can create stress on their nervous system. Even a "normal, healthy" birth can induce 40-50 pounds of pressure on a newborn's neck and spine. [More]
Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes. [More]
Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year. [More]
Study finds negative health effects of anti-depressants

Study finds negative health effects of anti-depressants

Commonly prescribed anti-depressants appear to be doing patients more harm than good, say researchers who have published a paper examining the impact of the medications on the entire body. [More]
Advertisement
Advertisement